Placebo + ML-007C-MA BID + ML-007C-MA QD
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Jun 27, 2025 → Aug 1, 2026
NCT ID
NCT07038876About Placebo + ML-007C-MA BID + ML-007C-MA QD
Placebo + ML-007C-MA BID + ML-007C-MA QD is a phase 2 stage product being developed by MapLight Therapeutics for Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07038876. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07038876 | Phase 2 | Recruiting |
Competing Products
20 competing products in Schizophrenia